Market Newsdesk

TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) — iLOOKABOUT Corp. (TSXV:ILA) (“ILA” or “the Company”) today announced that its unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2020 and 2019, and the related Management’s Discussion and Analysis (“MD&A”) are available at www.sedar.com and on the Company’s website at http://www.ilookabout.com/investor-relations/financial-information. Shareholders may request a hard copy of this material by directing their request to: iLOOKABOUT Corp., Office of the CFO, 408-383 Richmond Street, London ON, N6A 3C4.

In the third quarter, the Company executed an Asset Purchase Agreement for the strategic acquisition of Apex Software (“Apex”), which is considered the industry standard for property building outline and sketch software in North America. This acquisition provides the Company with a vast growth opportunity by enabling the sale of ILA’s property tax platform to Apex’s 2,200+ property assessment clients, and also enabling the sale of Apex’s sketch software to ILA’s mortgage lending clients.

Also in the quarter, the Company closed a non-brokered private placement for aggregate gross proceeds of approximately $8 million, which BMO Capital Partners collaborated in. Subsequent to the third quarter, the Company further added to its capital resources by expanding its existing credit facilities with Bank of Montreal’s (“BMO”) Technology & Innovation Banking Group for an additional $4 million.

The Company continues to experience a high growth rate year-to-date, while executing several strategic initiatives for future growth. On a year-to-date basis, the Company has achieved 46% year-over-year revenue growth and 2% revenue growth for the third quarter on a year-over-year basis. However, the Company is still experiencing material impacts from the COVID-19 pandemic, which includes the continued moratorium on foreclosures in the United States (“US”). Although, with a focus on the mortgage origination and refinance market, the Company has added 12 new lending clients in the US. We also added 5 new clients and expanded our footprint with existing clients in our property tax business. The Company continues to maintain its austerity measures in response to the impact of COVID-19.

“Despite the impacts of COVID-19 on our business, we have successfully pivoted to implement new strategies to enable us to execute on our long term growth plans. We received significant demand in our recent capital raise, which validates our future growth plans,” said Gary Yeoman, Chair and Chief Executive Officer, “The future of our existing business is extremely positive, and we will continue to make accretive strategic investments to allow the company to grow and realise its full potential.”

Highlights of Financial Results:

		Unaudited							Unaudited
		Three months ended September 30							Nine months ended September 30
(In thousands of Canadian dollars)			2020			2019				2020			2019
Revenue		$	4,921		$	4,811			$	14,529		$	9,956
Adjusted EBITDA, Unaudited1			(189	)		(52	)			(1,537	)		739

Discussion with respect to the above noted results can be found in the Company’s MD&A.

¹ Adjusted EBITDA is an unaudited non-GAAP measure and does not have any standardized meaning prescribed under IFRS and, therefore, may not be comparable to similar measures employed by other reporting issuers. Management believes Adjusted EBITDA provides meaningful information with respect to the financial performance and value of the Company, as items that may obscure the underlying trends in the business performance are excluded. Adjusted EBITDA is defined and calculated by the Company as earnings (loss) before interest, taxes, depreciation/amortization of property and equipment, intangible assets and right-of-use assets, share-based compensation expense, foreign exchange gains (losses) recorded through profit and loss, and other costs or income that are: (i) non-operating; (ii) non-recurring; and/or (iii) are related to strategic initiatives. The Company classifies income or costs as non-recurring if income or costs similar in nature are not reasonably expected to occur within the next two years nor have occurred during the prior two years, and such costs are significant.

Forward Looking Information:

This news release contains forward-looking statements that involve known and unknown risks, uncertainties and assumptions that may not be realized. These statements relate to future events or future performance and reflect management’s current expectations
and assumptions which are based on information currently available to management. There is significant risk that forward-looking statements will not prove to be accurate. A number of factors could cause actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements discussed in the forward-looking statements. The inclusion of forward-looking statements and information should not be regarded as a representation of ILA or any other person that the anticipated results will be
achieved
and investors are cautioned not to place undue reliance on such information.

These forward-looking statements are made as of the date of this news release and, accordingly, are subject to change after such date. ILA does not assume any obligation to update or revise this information to reflect new events or circumstances except as required in accordance with applicable laws.

About
ILA

ILA is a transformational data analytics organization that provides transparency to the valuation of real estate assets. ILA is a real estate valuation platform with technologies that leverage the power of data designed to address today’s dynamic real estate valuation market. Our proprietary innovative platform provides software and data licenses and technology managed services to the real estate industry, serving primarily the property lending and property tax sectors, both public and private, in the United States (“US”) and Canada. Accurate data and property valuations form the basis for our clients to value assets, fund loans, securitize portfolios and to analyze and update property tax assessments. As a fully integrated valuation technology company, we are setting new standards in real estate valuation quality and reliability. ILA is a brand built on innovation, execution, accuracy, industry expertise and forward-looking products and services.

ILA’s common shares are traded on the TSX Venture Exchange under the symbol ILA.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact:

Gary Yeoman, CEO [email protected] 416-347-7707 www.ilookabout.com

GUADALAJARA, Mexico, Nov. 27, 2020 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (NYSE: PAC; BMV: GAP) (the “Company” or “GAP”) announced that it has concluded the Extraordinary Review Process for the Master Development Program for the Mexican airports for the 2020 to 2024 period.

During the month of August, the Company filed a proposal for the adjustment of the Master Development Program (MDP) to the Aeronautical Authority, thus postponing investments by approximately 20 months. As such, certain investments that were scheduled to conclude in 2024 will now conclude in 2026.

In the new MDP, the same projects that were previously agreed upon with the authorities will remain, however, the initiation and termination timeframes will change; the scope of the projects will essentially remain the same.

The mandatory investment amounts of the Master Development Program that resulted from the Extraordinary Review were the following:

Airport	2020	2021	2022	2023	2024	TOTAL
Guadalajara	1,095,712	1,148,523	1,843,155	1,063,267	1,180,132	6,330,791
Tijuana	796,943	1,465,857	438,001	161,784	118,382	2,980,967
Los Cabos	395,869	496,216	272,952	236,278	177,928	1,579,243
Puerto Vallarta	205,956	450,956	660,397	901,625	807,678	3,026,612
Guanajuato	57,390	88,614	33,273	69,521	53,081	301,879
Hermosillo	57,959	93,970	53,066	29,849	56,805	291,649
La Paz	115,819	92,343	40,968	24,129	20,773	294,032
Mexicali	32,385	47,818	46,077	57,672	23,755	207,708
Aguascalientes	78,883	98,106	53,676	26,339	23,040	280,044
Morelia	32,716	51,576	35,098	50,682	19,510	189,582
Los Mochis	40,426	40,980	11,069	53,338	31,097	176,911
Manzanillo	26,439	48,629	30,176	21,757	15,670	142,671
TOTAL	2,936,500	4,123,588	3,517,909	2,696,240	2,527,851	15,802,088
Figures are expressed in thousands of Mexican pesos with acquisition power as of December 31, 2017; as such these will be updated based on the National Producer Price Index (NPPI), construction sector, upon execution.

 

As a result of the change in committed investments, as well as the remaining assumptions included in the Extraordinary Review, the new Maximum Tariffs that are applicable per workload unit are the following:

Airport	2021	2022	2023	2024
Guadalajara	216.86	215.34	213.83	212.33
Tijuana	165.57	164.41	163.26	162.12
Los Cabos	304.93	302.80	300.68	298.58
Puerto Vallarta	303.71	301.58	299.47	297.37
Guanajuato	226.89	225.30	223.72	222.15
Hermosillo	169.49	168.30	167.12	165.95
La Paz	186.65	185.34	184.04	182.75
Mexicali	162.06	160.93	159.80	158.68
Aguascalientes	175.50	174.27	173.05	171.84
Morelia	265.85	263.99	262.14	260.31
Los Mochis	192.76	191.41	190.07	188.74
Manzanillo	232.02	230.40	228.79	227.19
These passenger charges have been adjusted at an annual efficiency rate of 0.7% and are expressed in Mexican pesos as of December 31, 2017, as such, they will be updated per the National Producer Price Index (NPPI), excluding petroleum.

 

Company Description:

Grupo Aeroportuario del Pacífico, S.A.B. de C.V. (GAP) operates 12 airports throughout Mexico’s Pacific region, including the major cities of Guadalajara and Tijuana, the four tourist destinations of Puerto Vallarta, Los Cabos, La Paz and Manzanillo, and six other mid-sized cities: Hermosillo, Guanajuato, Morelia, Aguascalientes, Mexicali and Los Mochis. In February 2006, GAP’s shares were listed on the New York Stock Exchange under the ticker symbol “PAC” and on the Mexican Stock Exchange under the ticker symbol “GAP”. In April 2015, GAP acquired 100% of Desarrollo de Concesiones Aeroportuarias, S.L., which owns a majority stake in MBJ Airports Limited, a company operating Sangster International Airport in Montego Bay, Jamaica. In October 2018, GAP entered into a concession agreement for the operation of the Norman Manley International Airport in Kingston, Jamaica. In October 2018, GAP entered into a concession agreement for the operation of the Norman Manley International Airport in Kingston, Jamaica and took control of the operation in October 2019.

This press release may contain forward-looking statements. These statements are statements that are not historical facts, and are based on management’s current view and estimates of future economic circumstances, industry conditions, company performance and financial results. The words “anticipates”, “believes”, “estimates”, “expects”, “plans” and similar expressions, as they relate to the company, are intended to identify forward-looking statements. Statements regarding the declaration or payment of dividends, the implementation of principal operating and financing strategies and capital expenditure plans, the direction of future operations and the factors or trends affecting financial condition, liquidity or results of operations are examples of forward-looking statements. Such statements reflect the current views of management and are subject to a number of risks and uncertainties. There is no guarantee that the expected events, trends or results will actually occur. The statements are based on many assumptions and factors, including general economic and market conditions, industry conditions, and operating factors. Any changes in such assumptions or factors could cause actual results to differ materially from current expectations.

In accordance with Section 806 of the Sarbanes-Oxley Act of 2002 and article 42 of the “Ley del Mercado de Valores”, GAP has implemented a “whistleblower” program, which allows complainants to anonymously and confidentially report suspected activities that June involve criminal conduct or violations. The telephone number in Mexico, facilitated by a third party that is in charge of collecting these complaints, is 01 800 563 00 47. The web site is www.lineadedenuncia.com/gap. GAP’s Audit Committee will be notified of all complaints for immediate investigation.

IR Contacts:
Saúl Villarreal, Chief Financial Officer	[email protected]
Alejandra Soto, IR, Finance and Financial Planning Manager	[email protected]
Gisela Murillo, Investor Relations	[email protected] / +52-33-3880-1100 ext.20294
Maria Barona, i-advize Corporate Communications	[email protected]

TORONTO, Nov. 27, 2020 (GLOBE NEWSWIRE) — Waypoint Investment Partners Inc. (Waypoint) today announced the refiling of the Interim Management Report of Fund Performance (MRFP) for Waypoint All Weather Alternative Fund (the Fund). The purpose of the refiling is to:

• correctly label the MRFP as Interim Management Report of Fund Performance which was improperly labelled as Annual Management Report of Fund Performance;
• include the trading expense ratio for the Fund which is 1.13% and was incorrectly stated;
• include information on the net asset value per unit at the end of the period which was omitted in the first chart under “Financial Highlights”; and
• include information on the management expense ratio before waivers or absorptions which was omitted.

The effect on the Fund of these corrections was immaterial and no other changes were made to the MRFP. The refiled MRFP will be available on the Fund’s website at http://www.waypointinvestmentpartners.com/funds.html and on SEDAR at www.sedar.com.

Commissions, trailing commissions, management fees, and expenses all may be associated with investments in the Fund. Please read the prospectus and Fund Facts before purchasing the Fund. The Fund is not guaranteed. The net asset value of the Fund changes frequently and past performance may not be repeated.

For further information on Waypoint and the Fund, please visit www.waypointinvestmentpartners.ca.

ABOUT WAYPOINT INVESTMENT PARTNERS

Waypoint Investment Partners Inc. is a Toronto-based investment manager that services high net worth individuals, family offices, investment advisors, foundations and institutional clients. With a team of 10 experienced industry professionals, Waypoint delivers unique and proprietary products and services. Waypoint is a member of the Portfolio Management Association of Canada and is registered as an Investment Fund Manager, Portfolio Manager and Exempt Market Dealer in several Canadian provinces.

For further information, please contact Max Torokvei, Partner & Chief Executive Officer, [email protected], (416) 960-7683.

ISS
Acknowledges Ziopharm’s
Outperformance
of
its Peer Group
During
Chairman Scott
Tarriff’s
Tenure

Court Filings R
aise Concerns About Professional Past of
WaterMill
Nominee Holger Weis

Ziopharm
Recommends Shareholders Return the GREEN Consent Revocation Card

BOSTON, Nov. 27, 2020 (GLOBE NEWSWIRE) — Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a response to a report issued by Institutional Shareholder Services (“ISS”) in connection with the consent solicitation initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”). In its report, ISS recommends that Ziopharm shareholders reject WaterMill’s attempt to remove half of the Ziopharm Board of Directors (the “Board”) and to vote against the addition of Mr. Postma to the Board. Ziopharm strongly recommends shareholders sign and return the Company’s GREEN Consent Revocation Card.

In a statement, the Company said:

“We
are gratified that ISS acknowledges
that
removing
half of Ziopharm’s Board
and replacing
them
with
WaterMill’s
full slate of proposed candidates – including Mr. Postma, himself – would not be in the best interest of shareholders or the Company
.
I
n addition, we are pleased that ISS acknowledges the track record of Ziopharm’s performance in recent years, which we believe underscores the long-term value potential in Ziopharm under the leadership of the curr
ent Board and management team.
I
mportantly, while we have a great deal of respect for ISS, the report contains
a number of
factual mistakes
. Additionally,
key information
in the public domain
relating
to
WaterMill
nominee Holger Weis
raises questions regarding his suitability as a director
.
”

The ISS report made clear several points relating to Ziopharm’s financial standing and performance, including by noting that “the company outperformed the median of its peer group since Tarriff assumed leadership of the board and since the company ended the Intrexon collaboration.”

However, Ziopharm’s management team and Board believe it is critical for shareholders to be aware of the following factual errors in the ISS report:

• ISS recommends in favor of fixing the Board size at seven, but their other recommendations would result in an eight-member board.
• ISS states that the Board “rejected” the resignations of Elan Ezickson and Dr. Scott Braunstein, but that is not correct. In fact, the Board never rejected these resignations. The Board promptly engaged two leading search firms to identify candidates in connection with the results of the 2020 annual meeting and has accepted resignations as soon as it has found suitable replacements.
• ISS reports Elan Ezickson attended “fewer than 75 percent of meetings in 2019”, which is not accurate. Mr. Ezickson attended nearly 90% of Board and committee meetings in 2019. Mr. Ezickson attended fewer than 75% of meetings the year before that only because he was unable to participate in two special Board meetings that were called on short notice.
• ISS’ review of Ziopharm’s material weakness is incorrect. The ISS report notes “there is nothing that prohibits the company from disclosing that remediation is underway,” when in fact Ziopharm has disclosed the remediation steps in several filings with the U.S. Securities and Exchange Commission (the “SEC”), including in its most recent Form 10-Q filed on November 5, 2020.
• ISS also critiques the Board for the “retention of an overboarded director,” but fails to note that the issue was remedied by the director’s resignation from another board well in advance of the launch of the consent solicitation.

Additionally, ISS recommends in favor of the election of WaterMill nominee Holger Weis arguing, among other things, that he “served on a public company board”. However, the Company has not found any evidence that Mr. Weis has public company board experience, an assessment supported in WaterMill’s own disclosures. Moreover, shareholders should consider the following publicly available information relating to WaterMill nominee Holger Weis:¹

• In July 2017, a majority of shareholders executed written consents to remove Mr. Weis as President, COO, and CFO of DemeRx, Inc. (“DemeRx”). Four days later, Mr. Weis resigned from the company.
• Less than a year after Mr. Weis’s departure, DemeRx filed for Chapter 11 bankruptcy. Importantly, in response to Mr. Weis’s creditor claim as part of the Chapter 11 bankruptcy filing, DemeRx claimed that Mr. Weis engaged in a breach of his fiduciary duties, corporate waste, misrepresentations of critical information to prospective shareholders about a clinical trial and misreporting of an FDA submission. Among other things, the DemeRx response notes the following:

“Weis made inaccurate and misleading presentations to the Board indicating that he had achieved certain performance benchmarks, when in fact he had not, resulting in the payment of cash bonuses and other excessive remuneration.”

“Weis engaged in corporate waste by awarding himself stock, a golden parachute, cash payments, and other excessive compensation based on milestones never achieved. Weis wrote


his own performa


nce evaluation. Weis painted a ‘rosy picture,’


overstated accomplishments and achievements and progress of a financing plan. Weis made unauthorized payments to himself on his last day of work, withdrawing all remaining funds from the


[


DemeRX’s


]


bank account. Weis also made certain to pay his future life insurance on his way out the door.”

“The FDA put


[


DemeRX’s


]


research project on a ‘full clinical hold’ in 2014. A potential i


nvestor,


Kieretsu


Capital LLC (‘


Kieretsu


’


) was interested in providing fundi


ng. Weis advised Keiretsu that ‘


Noribogaine


is now ready to


enter phase 2 clinical testing.’


But


DemeRx


was not ‘ready’ because of the FDA’s full clinical hold imposed in 2014. Weis also advised Keiretsu that


DemeRx


had ‘addressed the FDA’s concerns,’ which was materially inaccurate, as


DemeRx


had not contacted the FDA since the time the hold was imposed in 2014.”

“


During that time


Weis was in charge of


[


DemeRx


]


, it is estimated that Weis caused corporate waste, damages, and harm to


[


DemeRx


]


in the amount of approximately $10-12 million as the direct result of their acts and omissions, including complete and utter failure to implement adequate safeguards and controls and complete lack of oversight, that caused


[


DemeRx


]


to engage in activities and other improvident conduct beyond the scope of the PPM and that was otherwise fundamentally flawed


…


”

“Weis also ran up costs to


DemeRx


of over $868,000 in 2016 and incurring over $556,000 in debt to patent attorneys in 2016 when


D


emeRx


had already received the ‘going concern’


opinion from the outside independent auditors. Weis engaged in corporate waste


in regard to


excessive patent prosecution and foreign annuity costs, putting critical IP at risk of abandonment due to lack of funds.”

¹ Objection to Claim filed by DemeRx, Inc., Case 18-14149-RAM (Document 125), filed November 5, 2018.

Information related to the WaterMill consent solicitation can be found at www.ZiopharmForward.com.

About Ziopharm Oncology, Inc.

Ziopharm is developing non-viral and cytokine-driven cell and gene therapies that weaponize the body’s immune system to treat the millions of people globally diagnosed with a solid tumor each year. With its multiplatform approach, Ziopharm is at the forefront of immuno-oncology with a goal to treat any type of solid tumor. Ziopharm’s pipeline is built for commercially scalable, cost effective T-cell receptor T-cell therapies based on its non-viral Sleeping Beauty gene transfer platform, a precisely controlled IL-12 gene therapy, and rapidly manufactured Sleeping Beauty-enabled CD19-specific CAR-T program. The Company has clinical and strategic partnerships with the National Cancer Institute, The University of Texas MD Anderson Cancer Center and others. For more information, please visit www.ziopharm.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements regarding the business strategy, plans and objectives of Ziopharm management and expectations as to and beliefs about the Consent Solicitation initiated by WaterMill. Forward-looking statements include all statements that are not historical facts, and can be identified by terms such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “hope,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or similar expressions and the negatives of those terms. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Such risks and uncertainties include, among others, the impact and results of the Consent Solicitation and other shareholder activism activities by WaterMill and/or other activist investors, the risks and uncertainties disclosed in Ziopharm’s most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 as well as discussions of potential risks, uncertainties and other important factors in any subsequent filings by Ziopharm with the SEC. All information in this press release is as of the date hereof, and Ziopharm undertakes no duty to update the information, except as required by law.

Important Additional Information and Where to Find It

Ziopharm has filed a definitive consent revocation statement (the “Consent Revocation Statement”) together with a GREEN consent revocation card with the SEC in connection with the Consent Solicitation. SHAREHOLDERS ARE URGED TO READ THE CONSENT REVOCATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT ZIOPHARM FILES WITH THE SEC CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Consent Revocation Statement (including the GREEN consent revocation card), any amendments or supplements thereto and any other documents that Ziopharm files with the SEC from the SEC’s website (http://www.sec.gov) or from Ziopharm’s website (www.ziopharm.com) by clicking on “Investors” and then “SEC Filings.”

Investor Relations Contacts:

Adam D. Levy, PhD, MBA
EVP, Investor Relations and Corporate Communications
(508) 552-9255
[email protected]

Chris Taylor
VP, Investor Relations and Corporate Communications
(617) 502-1881
[email protected]

Michael Verrechia
Morrow Sodali
(212) 300-2476
[email protected]

Media Relations Contacts:

Chris Kittredge, Andrew Cole and Zachary Tramonti
Sard Verbinnen & Co.
[email protected]